Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00395421 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT00395421 is a Phase 2 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 114 participants.
The verdict
NCT00395421, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
This study is being conducted to see if the investigational medication, valopicitabine, is safe to use in combination with ribavirin, a drug approved by the FDA for treating hepatitis C infection.
Interventions
- DRUG NM283 plus Peg-IFNα-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00395421
The ClinicalTrials.gov registry entry for NCT00395421 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NM283 plus Peg-IFNα-2a is the first listed.
NCT00395421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00395421 about?
NCT00395421 is a clinical study titled "Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin". This study is being conducted to see if the investigational medication, valopicitabine, is safe to use in combination with ribavirin, a drug approved by the FDA for treating hepatitis C infection.
What is the current status of trial NCT00395421?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2006-10. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00395421?
The interventions under investigation include: NM283 plus Peg-IFNα-2a (DRUG).
Who is sponsoring clinical trial NCT00395421?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.